CSL 360

Drug Profile

CSL 360

Alternative Names: anti-CD123 mAb; CSL360; IL-3Rα

Latest Information Update: 20 Oct 2009

Price : $50

At a glance

  • Originator CSL
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 30 Sep 2009 CSL completes a phase I trial in Acute myeloid leukaemia in Australia
  • 22 Jan 2009 CSL 360 is still in phase I trials for Acute myeloid leukaemia in Australia
  • 11 Jan 2008 CSL Limited enteres into a development and supply agreement with Celltrion Inc. for CSL 360
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top